The immune system is powerful.
We make it precise!
About Us
​At Nova Immunobiology Therapeutics, we develop therapies that fine-tune immune responses. By targeting immune cell fate, we accelerate the discovery of treatments that are safer, faster, and more effective.
Our Approach
Targeting T Cell Biology.
We focus on:
-
CD8 T Cells - Overcoming exhaustion for durable anti-tumor and antiviral immunity.
-
Tfh Cells - Regulating antibody responses to infections and suppress autoimmunity.
-
Immune Modulators - Shaping T cell fate through transcriptional reprogramming.
From Discovery to Translation.
Targeting Immune Cell Modulation for Therapeutic Applications in Cancer, Autoimmunity, and Chronic Viral Infections.
Screening
Where discovery begins.
High-throughput small molecule discovery to identify novel immune modulators
Assay development
Enabling drug discovery and diagnostics
We utilize our strong in-house expertise to develop fit-for-purpose assays for drug discovery, diagnostics, and biomarker analysis in a fee-for-service model.
Validation
Proof through precision.
Rigorous functional assays confirm impact on T cell biology.
Therapeutic Development
From molecules to medicines.
Advancing validated candidates rapidly into oncology, autoimmunity, and viral infections.
Our Team
Meet the experts behind Nova Immunobiology Therapeutics, dedicated scientists with a passion for advancing immune modulation to transform patient care.
Founder
Devendra Rai, Ph.D., brings over 15 years of experience spanning industry, academia, and government. He has led high-impact programs from early discovery through FDA approval.
At Pfizer, he played a pivotal role in the discovery and development of PAXLOVID™ and spearheaded the advancement of Ibuzatrelvir, earning multiple internal awards for innovation. Earlier in his career, he successfully transferred ELISA diagnostic kit technology from the USDA to industry and secured two vaccine patents through inter-agency collaborations.
Dr. Rai has authored 58 publications, holds 2 patents, and has been cited more than 4,000 times. His research has been published in leading journals, including Science, Nature Medicine, and Science Advances, underscoring a career devoted to translating cutting-edge science into transformative therapies.
Currently an Associate Research Scientist in Immunobiology at Yale University, Dr. Aurobind Vidyarthi is an immunologist with expertise in immune regulation, cancer immunology, and host–pathogen interactions. His research has revealed how T cells and the immune microenvironment can be reprogrammed in infection and cancer, advancing insights that guide the development of innovative immunotherapies.
Co-Founder & Executive Director, Key2Meds
Stephen Mason brings over 25 years of experience in drug discovery and development across both small and large molecules. He played a pivotal role in the discovery of nirmatrelvir, the antiviral component of PAXLOVID. His career spans leadership roles at Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Johnson & Johnson. In addition to his industry experience, he advises biotech startups and is recognized for his expertise in antiviral research and broad knowledge across multiple therapeutic areas.
Tapan Agnihotri, Ph.D. (candidate) is pursuing his doctoral studies at McGill University, where his research focuses on immunometabolism and the regulation of immune cell function. His work centers on screening and evaluating molecules capable of modulating immune cell metabolism to inform new therapeutic strategies.
He has authored 7 peer-reviewed publications, cited more than 500 times, reflecting his growing contributions to the field of immune regulation and metabolism. Guided by curiosity and scientific rigor, Tapan’s research bridges fundamental discovery with translational applications in immunology.
Dr. Jawed A. Siddiqui is an Assistant Professor at the University of Mississippi Medical Center with over 15 years of research experience in cancer biology and bone metastasis. He has made pioneering contributions to understanding tumor–immune interactions within the bone microenvironment, with a focus on osteoimmunology and therapeutic targeting of metastatic niches. Dr. Siddiqui’s work has been supported by the Department of Defense, American Cancer Society, and METAvivor. He has authored more than 70 peer-reviewed publications and continues to lead innovative programs advancing therapies for prostate, breast, lung, and kidney cancer bone metastasis.
